Reason for request

Own-initiative opinion by the transparency Committee for re assessment of Actual Benefit (AB) and Improvement of Actual Benefit (IAB) in the indication “REVLIMID in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy” in accordance with Article R 163-21 of the social security code.


Clinical Benefit


The actual benefit offered by REVLIMID remains substantial.

Clinical Added Value


The Committee considers that, based on the currently available data, REVLIMID retains the moderate IAB (level III) assigned to it in 2007, in relation to the management of patients with multiple myeloma and who have already received at least one treatment.

Contact Us

Évaluation des médicaments

See also